摘要
To the Editor:Generalized pustular psoriasis(GPP)is a rare and severe form of psoriasis for which traditional treatment approaches may not be effective.The traditional approach is systemic treatment with acitretin,methotrexate,and cyclosporin;however,obvious side effects often occur during drug administration,limiting their clinical application.Secukinumab,a fully human anti-interleukin(IL)-17A monoclonal antibody,demonstrates efficacy in treating moderate to severe plaque-type psoriasis.Nonetheless,there are limited evidence-based real-world data on GPP treatment with secukinumab.Two cases of GPP were successfully treated with secukinumab in Peking University Third Hospital recently.This study was approved by the Ethics Committee of our hospital(No.328-01).
